Acquisitions, Dispositions, and Deconsolidations - Life Sciences Segment (Details) - BeneVir - Life Sciences Segment |
Jun. 08, 2018
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Payment received | $ 72,800,000 |
Consideration paid | 106,700,000 |
Cash payment to be received upon release of escrow | 9,200,000 |
Payment to be received upon achievement of specified development milestones | 512,200,000.0 |
Pansend | |
Business Acquisition [Line Items] | |
Payment received | 93,400,000 |
Cash payment held in escrow | 13,300,000 |
Gain on sale of business | 102,100,000 |
Payment to be received upon achievement of specified development milestones | 189,700,000.0 |
Payments to be received upon achievement of specified levels of annual net sales of licensed products | 493,100,000.0 |
Pansend | Non-controlling Interest | |
Business Acquisition [Line Items] | |
Gain on sale of business | $ 21,700,000 |
Janssen Biotech, Inc. | |
Business Acquisition [Line Items] | |
Percentage of ownership interest acquired | 75.90% |
Cash paid in acquisition | $ 140,000,000 |
X | ||||||||||
- Definition Business Combination, Cash Payment Held In Escrow No definition available.
|
X | ||||||||||
- Definition Business Combination, Cash Payment To Be Received Upon Release of Escrow No definition available.
|
X | ||||||||||
- Definition Business Combination, Payments To Be Received Upon Achievement Of Specified Development Milestone No definition available.
|
X | ||||||||||
- Definition Business Combination, Payments To Be Received Upon Achievement Of Specified Levels Of Annual Net Sales Of Licensed products No definition available.
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|